216 related articles for article (PubMed ID: 26279064)
1. Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells.
Scharow A; Raab M; Saxena K; Sreeramulu S; Kudlinzki D; Gande S; Dötsch C; Kurunci-Csacsko E; Klaeger S; Kuster B; Schwalbe H; Strebhardt K; Berg T
ACS Chem Biol; 2015 Nov; 10(11):2570-9. PubMed ID: 26279064
[TBL] [Abstract][Full Text] [Related]
2. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
Shin SB; Woo SU; Yim H
J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
[TBL] [Abstract][Full Text] [Related]
4. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.
Yuan J; Sanhaji M; Krämer A; Reindl W; Hofmann M; Kreis NN; Zimmer B; Berg T; Strebhardt K
Am J Pathol; 2011 Oct; 179(4):2091-9. PubMed ID: 21839059
[TBL] [Abstract][Full Text] [Related]
5. Poloxin-2HT+: changing the hydrophobic tag of Poloxin-2HT increases Plk1 degradation and apoptosis induction in tumor cells.
Rubner S; Schubert S; Berg T
Org Biomol Chem; 2019 Mar; 17(12):3113-3117. PubMed ID: 30848278
[TBL] [Abstract][Full Text] [Related]
6. Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay.
Normandin K; Lavallée JF; Futter M; Beautrait A; Duchaine J; Guiral S; Marinier A; Archambault V
Sci Rep; 2016 Nov; 5():37581. PubMed ID: 27874094
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
Berg A; Berg T
Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918
[TBL] [Abstract][Full Text] [Related]
8. Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells.
Ritter A; Friemel A; Kreis NN; Louwen F; Yuan J
Oncotarget; 2016 Dec; 7(51):84271-84285. PubMed ID: 27713178
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells.
Qin T; Chen F; Zhuo X; Guo X; Yun T; Liu Y; Zhang C; Lai L
J Med Chem; 2016 Aug; 59(15):7089-96. PubMed ID: 27425654
[TBL] [Abstract][Full Text] [Related]
10. Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators.
Archambault V; Normandin K
Cell Cycle; 2017 Jun; 16(12):1220-1224. PubMed ID: 28521657
[TBL] [Abstract][Full Text] [Related]
11. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
Kreis NN; Louwen F; Zimmer B; Yuan J
Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
[TBL] [Abstract][Full Text] [Related]
12. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
Scharow A; Knappe D; Reindl W; Hoffmann R; Berg T
Chembiochem; 2016 Apr; 17(8):759-67. PubMed ID: 26634982
[TBL] [Abstract][Full Text] [Related]
13. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Shan HM; Shi Y; Quan J
ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
[TBL] [Abstract][Full Text] [Related]
15. Selective Degradation of Polo-like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Polo-Box Domain.
Rubner S; Scharow A; Schubert S; Berg T
Angew Chem Int Ed Engl; 2018 Dec; 57(52):17043-17047. PubMed ID: 30351497
[TBL] [Abstract][Full Text] [Related]
16. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
17. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
Chapagai D; Ramamoorthy G; Varghese J; Nurmemmedov E; McInnes C; Wyatt MD
J Med Chem; 2021 Jul; 64(14):9916-9925. PubMed ID: 34210138
[TBL] [Abstract][Full Text] [Related]
18. Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.
Chen F; Zhuo X; Qin T; Guo X; Zhang C; Lai L
Chem Biol Drug Des; 2017 May; 89(5):732-740. PubMed ID: 27882722
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the Allosteric Communication between the Polo-Box Domain and the Catalytic Domain in Plk1 by Small Compounds.
Raab M; Sanhaji M; Pietsch L; Béquignon I; Herbrand AK; Süß E; Gande SL; Caspar B; Kudlinzki D; Saxena K; Sreeramulu S; Schwalbe H; Strebhardt K; Biondi RM
ACS Chem Biol; 2018 Aug; 13(8):1921-1931. PubMed ID: 29927572
[TBL] [Abstract][Full Text] [Related]
20. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chembiochem; 2009 May; 10(7):1145-8. PubMed ID: 19350612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
